Efzimfotase Alfa Shows Numerical Gain but Misses Statistical Significance in HICKORY Hypophosphatasia Trial
Efzimfotase alfa, also known as ALXN1850, posted a numerical improvement in the phase 3 HICKORY trial for adolescents and adults with hypophosphatasia, but the study did not meet statistical significance on its primary walking endpoint. The outcome leaves the program with a signal of biological activity and a clear statistical miss in a disorder where skeletal fragility, muscle weakness, and impaired mobility can sharply limit day-to-day function.
The primary endpoint was the change from baseline in the Six-Minute Walk Test at week 25 among participants aged 12 years and older who had not previously been treated with STRENSIQ (asfotase alfa). In the overall population, efzimfotase alfa produced a least squares mean difference of 17.05 meters versus placebo, with a p value of 0.1675. The result did not cross the threshold required for statistical significance, and the company attributed much of the shortfall to better-than-expected performance in the adult-onset hypophosphatasia placebo group.
A walking signal without a statistically persuasive p value is still clinically interesting in a disease defined by impaired mineralization and loss of physical reserve.
Walking Performance Remained the Core Readout
The six-minute walk test is a blunt but useful measure in hypophosphatasia because it captures more than leg strength alone. It reflects pain, fatigue, balance, proximal muscle function, and the skeletal mechanics that determine whether a patient can sustain ambulation over a short interval. In adults and adolescents with untreated disease, gains of even modest size can matter, especially when baseline function is constrained by chronic disease burden.
The trial also included a post hoc analysis using minimum clinically important difference thresholds set at 43 meters for adolescents and 31.1 meters for adults. At week 25, 45.2% of patients treated with efzimfotase alfa achieved that threshold, compared with 30.0% of patients in the placebo group. Post hoc findings cannot substitute for a prespecified primary analysis, but they do support the possibility that a subset of patients may derive meaningful functional benefit even when the overall study does not clear its statistical bar.
HYPOTHETICAL mechanistic speculation is not needed here; the pathophysiology is straightforward. Hypophosphatasia stems from deficient tissue-nonspecific alkaline phosphatase activity, which disrupts bone mineralization and can impair musculoskeletal performance across age groups. An enzyme replacement strategy aims to correct that metabolic bottleneck, and a functional endpoint such as the six-minute walk test is well suited to detect whether improved mineral handling translates into better mobility.
The Placebo Arm Shaped the Trial Outcome
The most consequential feature of the readout was not a treatment-related safety issue or a catastrophic lack of signal. It was the unexpectedly strong response in the adult-onset placebo group, which narrowed the separation between arms and weakened the study’s statistical power at week 25. In practical terms, the treatment arm moved in a positive direction, but the comparator arm moved enough to make the difference less convincing on paper.
That kind of result is familiar in rare-disease trials, where small sample sizes magnify the effect of natural variability, regression toward the mean, and baseline heterogeneity. In a condition as clinically mixed as hypophosphatasia, adult-onset disease may not behave identically to adolescent disease, and pooled analyses can blur real biologic differences between subgroups. A phase 3 trial built on a single mobility endpoint can therefore be vulnerable to precisely this sort of statistical collision between true drug effect and unexpected placebo performance.
Safety Signals Were Not the Issue
Safety did not emerge as the limiting factor in the readout provided. The announcement focused on efficacy, not on a concerning adverse-event pattern, and the central message was the absence of statistical significance rather than any new toxicity signal. For an enzyme replacement therapy in a chronic metabolic bone disorder, that distinction matters to clinicians deciding whether the program has enough support to justify further development.
A numerically favorable efficacy result with no major safety warning leaves the door open for continued interpretation, especially if other endpoints or subgroup patterns are later reported. Still, a missed primary endpoint in phase 3 places the burden squarely on any secondary analyses, additional datasets, or future studies to clarify whether the apparent activity can be reproduced and in whom it is strongest.
What the Result Means for Hypophosphatasia Care
For clinicians caring for patients with hypophosphatasia, the HICKORY result is a reminder that rare bone disorders are judged on both structure and function. A therapy can influence the underlying enzymatic defect and still fall short on a mobility endpoint if the study population is too heterogeneous, the placebo group performs unusually well, or the treatment effect is modest over the observation window. The 17.05-meter numerical advantage suggests a directional signal, but not one strong enough to anchor a regulatory claim on its own.
The post hoc minimum clinically important difference analysis will likely draw attention because it translates the raw walking data into a threshold that feels more bedside-relevant. Even so, post hoc responder analyses are hypothesis-generating, not definitive. They are most useful when they help identify which patients, disease stages, or baseline functional profiles may be most likely to respond in a subsequent trial or extension study.
For now, the HICKORY readout leaves efzimfotase alfa in an in-between position: biologically plausible, numerically favorable, and statistically unconfirmed on the primary endpoint. In a field where treatment options are limited and mobility loss carries lasting consequences, that is not a trivial distinction. It is the difference between encouraging movement in the right direction and proving that the effect is real enough to change routine practice.